Literature DB >> 34152827

Combined Immunosuppressive Therapy for Severe Graves Dermopathy.

Sriram Gubbi1, Katherine Andrea Araque1, Shirisha Avadhanula2, Asma Azam1, Roxanne Merkel1, Craig Cochran1, Peter Denis Burbelo3, Meryl Waldman1, Susanne Neumann1, Marvin Carl Gershengorn1, Monica Skarulis1, Joanna Klubo-Gwiezdzinska1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34152827      PMCID： PMC9473454          DOI： 10.7326/L21-0152

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   51.598


× No keyword cloud information.
  5 in total

1.  Treatment-resistant elephantiasic thyroid dermopathy responding to rituximab and plasmapheresis.

Authors:  Christopher Heyes; Richard Nolan; Michael Leahy; Kurt Gebauer
Journal:  Australas J Dermatol       Date:  2010-09-10       Impact factor: 2.875

Review 2.  Pretibial myxedema: pathophysiology and treatment options.

Authors:  Vahab Fatourechi
Journal:  Am J Clin Dermatol       Date:  2005       Impact factor: 7.403

3.  Clinical Experience with Rituximab and Intravenous Immunoglobulin for Pretibial Myxedema: A Case Series.

Authors:  Anupam Kotwal; Adina F Turcu; Vikram Sonawane; Rebecca S Bahn; Mark R Pittelkow; Alina Bridges; Marius N Stan
Journal:  Thyroid       Date:  2019-04-08       Impact factor: 6.568

4.  Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.I.

Authors:  Sepideh S Farivar; William E Cunningham; Ron D Hays
Journal:  Health Qual Life Outcomes       Date:  2007-09-07       Impact factor: 3.186

5.  Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study.

Authors:  Joanna Klubo-Gwiezdzinska; Maria Lange; Elaine Cochran; Robert K Semple; Cornelia Gewert; Rebecca J Brown; Phillip Gorden
Journal:  Diabetes Care       Date:  2018-09-10       Impact factor: 19.112
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.